- Home
- GRPN vs CRVS Comparison
GRPN vs CRVS Comparison
Compare GRPN & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRPN
- CRVS
- Stock Information
- Founded
- GRPN 2008
- CRVS 2014
- Country
- GRPN United States
- CRVS United States
- Employees
- GRPN N/A
- CRVS N/A
- Industry
- GRPN Advertising
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- GRPN Consumer Discretionary
- CRVS Health Care
- Exchange
- GRPN Nasdaq
- CRVS Nasdaq
- Market Cap
- GRPN 1.4B
- CRVS 305.4M
- IPO Year
- GRPN 2011
- CRVS 2016
- Fundamental
- Price
- GRPN $37.49
- CRVS $4.02
- Analyst Decision
- GRPN Buy
- CRVS Strong Buy
- Analyst Count
- GRPN 4
- CRVS 4
- Target Price
- GRPN $29.00
- CRVS $15.00
- AVG Volume (30 Days)
- GRPN 1.5M
- CRVS 1.2M
- Earning Date
- GRPN 07-29-2025
- CRVS 08-05-2025
- Dividend Yield
- GRPN N/A
- CRVS N/A
- EPS Growth
- GRPN N/A
- CRVS N/A
- EPS
- GRPN N/A
- CRVS N/A
- Revenue
- GRPN $486,660,000.00
- CRVS N/A
- Revenue This Year
- GRPN $3.48
- CRVS N/A
- Revenue Next Year
- GRPN $8.16
- CRVS N/A
- P/E Ratio
- GRPN N/A
- CRVS N/A
- Revenue Growth
- GRPN N/A
- CRVS N/A
- 52 Week Low
- GRPN $7.75
- CRVS $1.77
- 52 Week High
- GRPN $41.26
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- GRPN 69.14
- CRVS 51.62
- Support Level
- GRPN $35.23
- CRVS $3.79
- Resistance Level
- GRPN $41.26
- CRVS $4.09
- Average True Range (ATR)
- GRPN 1.96
- CRVS 0.28
- MACD
- GRPN -0.17
- CRVS -0.02
- Stochastic Oscillator
- GRPN 55.17
- CRVS 56.90
About GRPN Groupon Inc.
Groupon Inc acts as the middleman between consumers and merchants, offering products and services at discounts via its online store. It offers consumers daily deals from local merchants. The company's operations are organized into two segments: North America and International. The company generates the majority of its revenue from North America. The company generates revenue from transactions during which the company generates commissions by selling goods or services on behalf of third-party merchants. Revenue also includes commissions the company earn when customers make purchases with retailers using digital coupons accessed through its digital properties.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).